YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

SHSC:1558 Stock Report

Market Cap: HK$8.2b

YiChang HEC ChangJiang Pharmaceutical Management

Management criteria checks 3/4

YiChang HEC ChangJiang Pharmaceutical's CEO is Juncai Jiang, appointed in May 2015, has a tenure of 9.58 years. total yearly compensation is CN¥2.57M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 0.008% of the company’s shares, worth HK$624.48K. The average tenure of the management team and the board of directors is 7.4 years and 7.4 years respectively.

Key information

Juncai Jiang

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentage18.7%
CEO tenure9.6yrs
CEO ownership0.008%
Management average tenure7.4yrs
Board average tenure7.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Juncai Jiang's remuneration changed compared to YiChang HEC ChangJiang Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥3mCN¥482k

CN¥2b

Sep 30 2023n/an/a

CN¥2b

Jun 30 2023n/an/a

CN¥1b

Mar 31 2023n/an/a

CN¥608m

Dec 31 2022CN¥1mCN¥600k

CN¥77m

Sep 30 2022n/an/a

-CN¥18m

Jun 30 2022n/an/a

-CN¥113m

Mar 31 2022n/an/a

-CN¥351m

Dec 31 2021CN¥1mCN¥490k

-CN¥588m

Sep 30 2021n/an/a

-CN¥436m

Jun 30 2021n/an/a

-CN¥285m

Mar 31 2021n/an/a

CN¥277m

Dec 31 2020CN¥756kCN¥229k

CN¥839m

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥2b

Mar 31 2020n/an/a

CN¥2b

Dec 31 2019CN¥393kCN¥222k

CN¥2b

Sep 30 2019n/an/a

CN¥2b

Jun 30 2019n/an/a

CN¥1b

Mar 31 2019n/an/a

CN¥1b

Dec 31 2018CN¥365kCN¥209k

CN¥943m

Sep 30 2018n/an/a

CN¥961m

Jun 30 2018n/an/a

CN¥980m

Mar 31 2018n/an/a

CN¥813m

Dec 31 2017CN¥324kCN¥194k

CN¥647m

Compensation vs Market: Juncai's total compensation ($USD352.37K) is about average for companies of similar size in the Hong Kong market ($USD478.93K).

Compensation vs Earnings: Juncai's compensation has increased by more than 20% in the past year.

CEO

Juncai Jiang (42 yo)

9.6yrs

Tenure

CN¥2,572,000

Compensation

Mr. Juncai Jiang has been General Manager and Executive Director of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. since joining in May 2015. Mr. Jiang served as Deputy Head of the traditional Chinese med...

Leadership Team

NamePositionTenureCompensationOwnership
Juncai Jiang
GM & Executive Director9.6yrsCN¥2.57m0.0076%
HK$ 624.5k
Yangui Chen
Head of the Sales Department10.6yrsCN¥645.00kno data
Danjin Wang
Deputy GM & Executive Director9.6yrsCN¥2.71m0.0076%
HK$ 628.6k
Shuang Li
Deputy GM & Executive Director9.6yrsCN¥1.32m0.0076%
HK$ 624.5k
Hao Chen
Executive Director1.3yrsCN¥1.59mno data
Qiang Zhang
CFO & Head of Finance Department5.8yrsCN¥480.38kno data
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.4yrsno data0.0036%
HK$ 299.5k
Qiyun Peng
Joint Company Secretary6.2yrsCN¥370.31kno data
Wai Chiu Wong
Joint Company Secretary2.8yrsno datano data

7.4yrs

Average Tenure

43yo

Average Age

Experienced Management: 1558's management team is seasoned and experienced (7.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Juncai Jiang
GM & Executive Director9.6yrsCN¥2.57m0.0076%
HK$ 624.5k
Danjin Wang
Deputy GM & Executive Director18.8yrsCN¥2.71m0.0076%
HK$ 628.6k
Shuang Li
Deputy GM & Executive Director6.5yrsCN¥1.32m0.0076%
HK$ 624.5k
Hao Chen
Executive Director1.3yrsCN¥1.59mno data
Shengchao Wang
Chief of Quality Division & Employee Representative Supervisor7.4yrsno data0.0036%
HK$ 299.5k
Xinfa Tang
Non-Executive Chairman9.6yrsCN¥32.19m0.015%
HK$ 1.2m
Jianxin Tang
Independent Non-Executive Director9.6yrsCN¥100.00kno data
Zhonghua Luo
Supervisor7.5yrsno data0.0076%
HK$ 624.5k
Jinlong Tang
Chairman of the Board of Supervisors5.5yrsno datano data
Ling Xiang
Independent Non Executive Director4.5yrsCN¥100.00kno data
Xuechen Li
Independent Non-Executive Director4.3yrsCN¥340.00k0.00045%
HK$ 37.0k

7.4yrs

Average Tenure

46yo

Average Age

Experienced Board: 1558's board of directors are considered experienced (7.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 18:55
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Ling ZhangChina Merchants Securities (HK) Co., Ltd
null nullCMB International Securities Limited